Conavi Medical Corp. (TSXV:CNVI)
Canada · Delayed Price · Currency is CAD 0.1800
-0.0100 (-5.26%)
Aug 20, 2026, 3:56 PM EST
Conavi Medical Income Statement
Financials in millions CAD. Fiscal year is October - September.
Millions CAD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
| 0.78 | 9.12 | 2.16 | 2.36 | 2.7 | |
Revenue Growth | -91.87% | 322.12% | -8.59% | -12.44% | - |
Cost of Revenue | 0.03 | 1.5 | 2.11 | 0.96 | 1.01 |
Gross Profit | 0.74 | 7.63 | 0.05 | 1.4 | 1.69 |
Selling, General & Admin | 7.52 | 6.15 | 7.07 | 6.3 | 5.22 |
Research & Development | 11.56 | 15.27 | 17.94 | 15.2 | 5.58 |
Other Operating Expenses | 0.34 | 0.25 | 0.29 | 0.23 | 0.09 |
Operating Expenses | 20.18 | 22.48 | 26.29 | 23.03 | 11.98 |
Operating Income | -19.44 | -14.85 | -26.23 | -21.63 | -10.28 |
Interest Expense | -0.94 | -11.69 | -8.02 | -5.64 | -4.09 |
Interest & Investment Income | 0.14 | 0.14 | 0.25 | 0.28 | 0.05 |
Currency Exchange Gain (Loss) | 0.9 | -0.07 | -0.55 | 0.76 | 2.47 |
Other Non Operating Income (Expenses) | 1.24 | 10.94 | - | - | - |
EBT Excluding Unusual Items | -18.09 | -15.53 | -34.55 | -26.22 | -11.87 |
Gain (Loss) on Sale of Investments | - | - | - | 0.13 | - |
Other Unusual Items | 0.24 | -4.99 | -9.07 | - | - |
Pretax Income | -17.85 | -20.52 | -43.62 | -26.09 | -11.87 |
Net Income | -17.85 | -20.52 | -43.62 | -26.09 | -11.87 |
Net Income to Common | -17.85 | -20.52 | -43.62 | -26.09 | -11.87 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 81 | 58 | 6 | 6 | 6 |
Shares Outstanding (Diluted) | 81 | 58 | 6 | 6 | 6 |
Shares Change | 233.30% | 833.52% | 0.08% | 0.00% | - |
EPS (Basic) | -0.22 | -0.36 | -7.08 | -4.24 | -1.93 |
EPS (Diluted) | -0.22 | -0.36 | -7.08 | -4.24 | -1.93 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Free Cash Flow | -23.74 | -25.17 | -20.72 | -20.66 | -9.78 |
Free Cash Flow Per Share | -0.29 | -0.44 | -3.36 | -3.36 | -1.59 |
Gross Margin | 95.63% | 83.61% | 2.45% | 59.22% | 62.67% |
Operating Margin | -2498.20% | -162.81% | -1213.93% | -914.76% | -380.89% |
Profit Margin | -2294.22% | -224.91% | -2018.28% | -1103.51% | -439.52% |
Free Cash Flow Margin | -3050.90% | -275.96% | -958.95% | -874.07% | -362.22% |
EBITDA | -19.01 | -14.37 | -25.6 | -20.71 | -9.61 |
EBITDA Margin | - | -157.49% | - | - | - |
D&A For EBITDA | 0.42 | 0.49 | 0.64 | 0.92 | 0.67 |
EBIT | -19.44 | -14.85 | -26.23 | -21.63 | -10.28 |
EBIT Margin | - | -162.81% | - | - | - |
Revenue as Reported | 0.78 | 9.12 | 2.16 | 2.36 | 2.7 |